24th Post-ASH meeting 2022
Ann Janssens (UZ Leuven, Belgium)
President of BHS
Prof. Ann Janssens is Head of Clinics in the Department of Hematology at Leuven University Hospital, Leuven, Belgium. She obtained her medical degree from the University of Ghent, before specializing there in hematology. In vitro apoptosis and clonal evolution in chronic lymphocytic leukemia (CLL) was the title of her doctoral thesis.
Prof. Janssens has a special interest in CLL and other indolent lymphomas and also in immune thrombocytopenias (ITP). She acts as a co-ordinator for Phase I–IV clinical studies relating to CLL-low grade lymphomas and ITP. She has published in several peer-reviewed journals. She is a member of the editorial board of The Belgian Journal of Hematology. Since 2019 she is the President of the Belgian Hematological Society.
Marc André (CHU-UCL Namur, Belgium)
BHS Vice-President
I am currently Professor of Hematology and Medicine and Chair of the Department of Hematology and Internal medicine at the Centre Hospitalier Universitaire UCL Namur, Yvoir, Belgium. I have extensive experience in clinical and laboratory research in lymphoma, and a particular interest in Holdgkin lymphoma and late toxicities of treatments.  I have personally conducted or been involved in more than 50 clinical studies in the field of lymphoma, either early phase clinical trials or larger-scale studies, national or international, such as the large-scale clinical trial H10 (André et al. JCO 2017) on Hodgkin lymphoma. I am currently involved as principal investigator or steering committee member in several clinical trials evaluating new agents or innovative therapeutic strategies in lymphoma. I have assumed leadership positions in lymphoma related research projects: since 2012, I have been serving as Hodgkin committee Chairperson of the international cooperative group LYSA (The Lymphoma Study association), which is, currently, conducting over 40 clinical and translational studies, from phase I/II trials to phase III studies, some of them performed in partnership with industrial entities and used for registration of new agents.  I have served for 6 years as member of the board of the Belgian Hematology Society and I serve since 3 years as Vice-President of this Society. Finally, I have also undertaken over the years multiple institutional and scientific responsibilities in CHU UCL Namur, Belgium (Head of Internal Medicine department) and the University Catholic de Louvain and Université de Namur.
Mariëlle Beckers (UZ Leuven, Leuven, Belgium)
Mariëlle Beckers is a hematologist at the University Hospital Leuven where she focuses on the treatment of myelodysplastic syndrome (MDS).  She studied medicine at the KU Leuven and received her specialist training at the University Medical Center Utrecht and Maastricht University Medical Center, Netherlands. Besides participating in clinical trials her research focuses on diagnosis of MDS and immunological research in hematological malignancies. Currently, she is chair of the MDS subcommittee of the Belgian Hematology Society (BHS) and is an active member of several scientific organizations like BHS, HOVON (Acute Leukemia working party) and the EBMT (Chronic Leukemia Working Party). 
Ann De Becker (UZ Brussel, Brussels, Belgium)
Ann De Becker obtained her medical degree from the Vrije Universiteit Brussel (VUB) and is currently a haematologist a UZ Brussel. There she focuses on treatment of acute leukemias, stem cell transplantation and apheresis. She is also actively involved in stem cell research in the Stem Cell Laboratory of UZ Brussel-VUB.   She is a member of national and international Hematology associations and participates in the BHS acute leukemia, stem cell transplantation and myelodysplastic syndrome committees. 
Ciel De Vriendt (UZ Gent, Ghent, Belgium)
Ciel De Vriendt (°1986) is a haematologist at Ghent University Hospital. After studying medicine at Ghent University, she completed her specialisation in haematology at UZ Gent. For her manama in internal medicine, she studied aggressive B-cell lymphomas (Abstract 105297, ASH 2017, Blood, Volume 130, Supplement 1, Page 1577). The elaboration on underlying Inborn Error of Immunity or familial predisposition in lymphoproliferative and plasma cell disorders are the subject of her doctoral research in the coming years. In 2017, Dr De Vriendt was the first laureate of the BHS Educational Course. She is a member of the Belgian Hematology Society (BHS) Lymphoma Committee and the Women in Lymphoma (About Us | Women in Lymphoma) group, in addition to being a member of the Belgian Primary Immunodeficiency Group (BPIG) and European Society of Immunodeficiency (ESID) driven by her fascination of lymphomagenesis in these unique patient population. She gained additional clinical experience in the LYSA-center of Prof. Gilles Salles and now Hervé Ghesquières in Lyon (Centre Hospitalier Lyon-Sud) where she completed a fellowship with special emphasis on CAR-T cell therapy.  For her current clinical practice she is focused on immunodeficiency and lymphoproliferative diseases with the emphasis on aggressive lymphomas and immunotherapy where she collaborate in academic research (scientific) with a project on Shallow Whole Genome Sequencing (SWGS) for Diagnosis and Monitoring of Aggressive Lymphoma Disease in Liquid Biopsy, in collaboration with the Department of Pathology (Haematologica. 2020).  
Cedric Hermans (UCLouvain, Belgium)
Cedric Hermans currently heads the Division of Haematology, the Hemostasis and Thrombosis Unit as well as the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium. He was appointed Associate Professor at the Medical School of the Catholic University of Louvain in 2003, Full Professor in 2012 and Vice-Dean in 2015. Professor Hermans has (co)-authored more than 300 original articles in international journals and is a member of several scientific societies and international advisory boards and collaborative research projects. He was president of EAHAD and is currently member of the Board of Directors of the World Federation of Haemophilia and the Editor-in-Chief of the Haemophilia Journal. His main research interests lie in the area of haemostasis and thrombosis, especially clinical studies on the treatment modalities and the wide spectrum of complications of haemophilia in both developed and developing countries, as well as new anticoagulants and the management of thrombosis.
Dominiek Mazure (UZ Gent, Ghent, Belgium)
Dominiek Mazure is a certified clinical hematologist working at the University Hospital Ghent. Her focus is treatment of myeloid disorders as myeloproliferative neoplasms and myelodysplastic syndromes, as well as care for stem cell transplant patients. She is also active on a national level to better the care for hematological patients as secretary of the BHS board and active member of the MPN and the MDS committee of the BHS.  
Chloé Spilleboudt (Institut Jules Bordet, Brussels, Belgium)
Chloé Spilleboudt obtained her medical degree at the ULB in 2006. In 2015 she finalized her specialization as hematologist. Currently she is working as a staff member in the Department of Hematology at the Institut Jules Bordet, Belgium. Her main clinical areas of interest include acute myeloid leukemia, myelodysplasia and allograft.  She is participating in several clinical trials as local principal investigator at Institut Jules Bordet. Dr.Spilleboudt is a member of the Belgian Hematology Society (BHS) and the European Hematology Association (EHA).   
Isabelle Vande Broek (VITAZ, Sint-Niklaas, Belgium)
Isabelle Vande Broek, MD, PhD, is a haematologist and head of Hematology at VITAZ Sint Niklaas (formely AZ Nikolaas) and AZ Sint Blasius Dendermonde.  She recieved her medical degree from the Free University Brussels and completed post-gradual training in Haematology and Internal Medicine at the same university. She obtained a doctoral degree in biomedical Sciences in 2005. Her main topic of research consisted of the role of the microenvironment in the pathogenesis of myeloma. She’s an active member of the Belgian Myeloma Subcommittee and the International Myeloma Working group (IMWG).